Cyxone in media
MedUni Vienna technology wins Recognition Prize in the science2business awards
A joint project between MedUni Vienna and Freiburg University Hospital, using cyclotides as a treatment for multiple sclerosis, was awarded the Recognition Prize in the science2business awards. This development is an example of a successful transfer of innovation from...
Read MoreMultiple sclerosis: plant peptide could prevent onset of the disease
MedUni Vienna has made a crucial development in the treatment of Multiple Sclerosis (MS): Together with his team and the research group led by Gernot Schabbauer, international partners from Australia, Germany and Sweden, Christian Gruber, Chief Researcher at the...
Read MoreSuccessful IPO with MedUni Vienna patent
Swedish company Cyxone, a subsidiary of ACCEQUA AB, headquartered in Malmö, recently went public – on the basis of a MedUni Vienna patent application relating to the potential development of an oral medication to combat multiple sclerosis. The invention...
Read MoreMultiple sclerosis: Plant peptide could prevent onset of the disease
https://www.sciencedaily.com/releases/2016/03/160329101244.htm
Read MoreOral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis
http://www.pnas.org/content/113/15/3960.full
Read MoreOral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis
http://www.pnas.org/content/early/2016/03/22/1519960113.full.pdf http://tvthek.orf.at/program/ZIB-1/1203/ZIB-1/12317916/Hoffnung-fuer-Multiple-Sklerose-Patienten/12318077
Read More